Composition comprising iota-carrageenan against viral Conjunctivitis

(19)

(11)

EP 2 898 888 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	12.06.2019 Bulletin 2019/24

(45)	Mention of the grant of the patent:
	24.04.2019 Bulletin 2019/17

(21)	Application number: 14152188.0

(22)	Date of filing: 22.01.2014

(51)

International Patent Classification (IPC):

A61K 9/00^(2006.01)
A61K 47/12^(2006.01)
A61K 47/26^(2006.01)
A61K 31/737^(2006.01)
A61P 31/12^(2006.01)

A61K 47/02^(2006.01)
A61K 47/18^(2017.01)
A61K 9/08^(2006.01)
A61K 31/731^(2006.01)

(54)	Composition comprising iota-carrageenan against viral Conjunctivitis Iota-Carrageenan enthaltende Zusammensetzung gegen virale Konjunktivitis Composition contenant de la carraghénane contre la conjonctivite virale

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Extension States:
	BA ME

(43)	Date of publication of application:
	29.07.2015 Bulletin 2015/31

(73)	Proprietor: VISUfarma B.V.
	1096 HA Amsterdam (NL)

(72)	Inventors:
	Prieschl-Grassauer, Eva 1220 Wien (AT) Morokutti-Kurz, Martina 1130 Wien (AT) Grassauer, Andreas 1220 Wien (AT) Nakowitsch, Sabine 1020 Wien (AT) Bodenteich, Angelika 1180 Wien (AT) König-Schuster, Marielle 1200 Wien (AT) Koller, Christiane 2200 Seying (AT)

(74)	Representative: Barchielli, Giovanna et al
	Bianchetti Bracco Minoja S.r.l. Via Plinio, 63 20129 Milano 20129 Milano (IT)

(56)

References cited: :

WO-A1-2010/000437

LEIBBRANDT ANDREAS ET AL: "Iota-Carrageenan Is a Potent Inhibitor of Influenza A Virus Infection", PLOS ONE, PUBLIC LIBRARY OF SCIENCE, US, vol. 5, no. 12, 1 December 2010 (2010-12-01), pages e14320-1, XP009159153, ISSN: 1932-6203 [retrieved on 2010-12-14]
MARTIN LUDWIG ET AL: "Efficacy of a Carrageenan nasal spray in patients with common cold: a randomized controlled trial", RESPIRATORY RESEARCH, BIOMED CENTRAL LTD., LONDON, GB, vol. 14, no. 1, 13 November 2013 (2013-11-13), page 124, XP021167455, ISSN: 1465-9921, DOI: 10.1186/1465-9921-14-124
WU E ET AL: "MEMBRANE COFACTOR PROTEIN IS A RECEPTOR FOR ADENOVIRUSES ASSOCIATED WITH EPIDEMIC KERSTOCONJUNCTIVITIS", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 78, no. 8, 1 April 2004 (2004-04-01), pages 3897-3905, XP008036328, ISSN: 0022-538X, DOI: 10.1128/JVI.78.8.3897-3905.2004

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).